<![CDATA[FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Solid Tumors Across Multiple Cancer Types]]>

<![CDATA[FDA Traditionally Approves Selpercatinib in RET+ Solid Tumors]]>

FDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid ...

The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progre

FDA Grants Full Approval to Selpercatinib for RET Fusion-Positive Solid ...

The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-posi

FDA Grants Traditional Approval to Retevmo for RET Fusion-Positive ...

The Food and Drug Administration (FDA) on July 14, 2026, granted traditional approval to Retevmo (selpercatinib) for adults and children 2 y

FDA Grants Traditional Approval to Selpercatinib for RET Fusion ...

Key Takeaways Traditional approval expands a tissue-agnostic option for RET fusion-positive solid tumors in patients aged ≥2 years after pro

FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced ...

The FDA has granted traditional approval to selpercatinib (Retevmo) for the treatment of adult and pediatric patients 2 years of age and old